For the year ending 2025-12-31, IKT has $181,204,516 in assets. $8,300,837 in debts.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 139,220,208 | |||
| Marketable securities | 39,543,820 | |||
| Prepaid research and development | 1,001,993 | |||
| Prepaid expenses and other current assets | 343,374 | |||
| Total current assets | 180,109,395 | |||
| Equipment and improvements, net | 0 | |||
| Right-of-use asset | 0 | |||
| Prepaid research and development, noncurrent | 1,000,000 | |||
| Amount held as a retainer | 95,121 | |||
| Total assets | 181,204,516 | |||
| Accounts payable | 1,158,054 | |||
| Lease obligation, current | 0 | |||
| Accrued expenses and other current liabilities | 4,081,282 | |||
| Contingent consideration liability | 3,061,501 | |||
| Total current liabilities | 8,300,837 | |||
| Total liabilities | 8,300,837 | |||
| Common stock, 0.001 par value 500,000,000 and 100,000,000 shares authorized 131,691,237 and 69,362,439 shares issued and outstanding (including 4,149,252 and 0 contingently issuable shares - see note 7) at december 31, 2025 and december 31, 2024, respectively | 131,691 | |||
| Additional paid-in capital | 315,429,986 | |||
| Accumulated other comprehensive income (loss) | 21,802 | |||
| Accumulated deficit | -142,679,800 | |||
| Total stockholders' equity | 172,903,679 | |||
| Total liabilities and stockholders' equity | 181,204,516 | |||
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)